Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 570
Rating:

Dr David Miller - The University of Texas Southwestern Medical Center

Dr Miller speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the phase III ZoptEC trial of zoptarelin, a doxarubicin-LHRH conjugate, versus doxarubicin alone for patients with advanced endometrial cancer who had not responded or relapsed after first-line therapy.

He describes how, contrary to phase II indications, zoptarelin had no effect on any endpoints, and the trial was negative.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation